Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: Monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction

American Journal of Transplantation

Volumn 2, Issue 7, 2002, Pages 671-673

  Jordan, Stanley C ^a   Vo, Ashley ^a   Bunnapradist, Suphamai ^a   Toyoda, Mieko ^a   Kamil, Elaine ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytomegalovirus (CMV) disease; Ganciclovir; Kidney transplantation

Indexed keywords

ACICLOVIR; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; STEROID; TACROLIMUS;

ADULT; ALGORITHM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; VIRUS LOAD;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036705544     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2002.20714.x     Document Type: Article

References (20)

1. Sagedal S, Nordal KP, Hartmann A et al. A prospective study of the natural course of cytomegalovirus disease and in renal allograft recipients. Transplantation 2000; 70: 1166-1174.
2. Pouteil-Noble C, Ecochard R, Landrivon G et al. Cytomegalovirus disease - an etiological factor for rejection? Transplantation 1993; 55: 851-857.
3. Fishman JA, Rubin RH. Disease in organ-transplant recipients. N Engl J Med 1998; 339: 1244-1246.
4. Fishman J, Doran M, Volpicelli S, Cosimi A, Flood J, Rubin R. Dosing of ganciclovir for the prophylaxis and treatment of CMV disease in solid organ transplant recipients, Transplantation 2000; 69: 389-394.
5. Turgeon N, Fishman J, Basgoz N et al. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent CMV in CMV seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Transplantation 1998; 66: 1780-1786.
6. Dunn DL, Gillingham KJ, Kramer MA et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus disease after solid organ transplantation. Transplantation 1994; 57: 876-884.
7. Birkeland S, Gahrn-Hansen B, Andersen H, Rohr N, Larsen KE, Jorgensen A. Cytomegalovirus prophylaxis in antibody-treated renal transplant patients. Transplant Proc 1995; 27: 3473-3476.
8. Brown DWG. The polymerase chain reaction (PCR) for human viral diagnosis. In: Clewly JP, ed. The Current Role of PCR in Diagnostic and Public Health Virology. Boca Raton, FL.: CRC Press; 1995.
9. Toyoda M, Zhang XM, Sun Z, Czer L, Trento A, Jordan SC. Use of polymerase chain reaction to rapidly detect cytomegalovirus DNA in peripheral blood leukocytes of transplant recipients. Transplant Proc 1995; 27: 1272-1273.
10. Toyoda MJB, Carlos O, Galera A et al. Correlation of cytomegalovirus DNA levels with response to antiviral therapy in cardiac and renal allograft recipients. Transplantation 1997; 63: 957-963.
11. Jiwa NMGW, Van Gemert A, Raap K et al. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction. Transplantation 1989; 48: 72-76.
12. Kidd IM, Fox JC, Pillay D, Charman H, Griffiths PD, Emery VC. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation 1993; 56: 867-871.
13. Schmidt CA, Oettle H, Peng R et al. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus disease after liver transplantation. Transplantation 1995; 59: 1133-1138.
14. The TH, van der Ploeg M, van den Berg AP, Vlieger AM, van der Giessen M, van Son WJ, Direct detection of cytomegalovirus in peripheral blood leukocytes - a review of the antigenemia assay and polymerase chain reaction. Transplantation 1992; 54: 193-198.
15. Yang CW, Kim YO, Kim YS et al. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay. Am J Nephrol 1998; 18: 373-378.
16. Fox JC, Kidd IM, Griffiths PD, Sweny P, Emery VC. Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with. J Gen Virol 1995; 76: 309-319.
17. Gerdes JCEK, Spees K. Fitting et al. Prospective study utilizing a quantitative polymerase chain reaction for detection of cytomegalovirus DNA in the blood of renal transplant patients. Transplant Proc 1993; 25: 1411-1413.
18. Kuhn JE, Wendland T, Schafer P et al. Monitoring of renal allograft recipients by quantitation of human cytomegalovirus genomes in peripheral blood leukocytes. J Med Virol 1994; 44: 398-405.
19. Kim WR, Badley AD, Wiesner RH et al. The economic impact of CMV disease after liver transplantation. Transplantation 2000; 69: 357-359.
20. Pescovitz DM, Rabkin J, Merion R et al. Valganciclovir provides ganciclovir plasma exposure similar to intravenous ganciclovir in transplant recipients. Transplantation 1999; 67: S126.